This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: Massachusetts Institute of Technology. Active years: 1994-2005.
Location History:
- Cerrboro, NC (US) (1994)
- Chapel Hill, NC (US) (1998 - 2001)
- Toronto, CA (2005)
Company Filing History:
Years Active: 1994-2005
Title: Caryn Y. Ito: Pioneering Researcher in the Field of Oncology
Introduction
Caryn Y. Ito is an innovative inventor based in Toronto, Canada, recognized for his contributions to the field of oncology through his patent work. With a total of four patents, Caryn has made significant strides in the localization and characterization of critical genes associated with various cancers.
Latest Patents
Caryn's latest patent revolves around the Wilms' tumor gene, which is associated with the 11p3 locus on the human chromosome. This innovation describes a method for analyzing cells for the presence of this gene. The Wilms' tumor gene encodes a transcription unit that is approximately 50 kb in size and produces an mRNA of about 3 kb. Notably, it is predominantly expressed in kidney and gonadal tissues. Furthermore, the gene undergoes alternative splicing, yielding four similar mRNA transcripts. The polypeptides encoded by the Wilms' tumor DNA feature four "zinc fingers" and a region rich in proline and glutamine, indicating a potential role in transcription regulation. Caryn's work in this area not only enhances the understanding of the genetic mechanisms underlying Wilms' tumor but also opens avenues for further research and potential therapeutic interventions.
Career Highlights
Caryn Y. Ito currently operates out of the Massachusetts Institute of Technology, where he has engaged in groundbreaking research. His work has significantly impacted the understanding of oncogenes and contributed to the body of knowledge that drives innovation in cancer treatment.
Collaborations
Throughout his career, Caryn has worked alongside esteemed colleagues such as Katherine M. Call and Thomas M. Glaser. These collaborations have undoubtedly enriched his research perspectives and resulted in substantial contributions to the field of genetics and oncology.
Conclusion
Caryn Y. Ito exemplifies the spirit of innovation in the scientific community, particularly in the study of oncogenes. His patents, particularly those related to the Wilms' tumor gene, underscore his commitment to advancing medical research and developing new diagnostic methods. As Caryn continues his work at the Massachusetts Institute of Technology, the potential for future breakthroughs in cancer understanding and treatment remains promising.